CTOs on the Move

Astellas

www.astellas.com

 
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Masashi Shimazaki
VP, Head of CI & Research Program Management in Oncology Research Profile
Wayne Berryman
Assistant Director Information Security Profile
Anand Pattabiraman
Senior Director of Information Systems Profile

Similar Companies

The Oregon Clinic

The Oregon Clinic is the largest private specialty physician practice in Oregon, with more than 200 providers practicing over 30 different medical and surgical specialties and sub-specialties. An evidence-based, multidisciplinary organization, The Oreg...

North Bend Medical Center

NBMC is a multi-specialty, regional medical center with more than 400 employees and 70 medical providers representing approximately 20 specialties

Cansortium

Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.

Circassia

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies.